Results 1 to 10 of about 22,383 (177)

Axial spondyloarthritis

Annals of the Rheumatic Diseases, 2021
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common presenting symptoms are chronic back pain and spinal stiffness but peripheral and extra-musculoskeletal manifestations occur also frequently.
Victoria Navarro-Compán, Alexandre Sepriano, Bassel El-Zorkany, Désirée van der Heijde   +3 more
  +6 more sources

Etanercept in axial spondyloarthritis

Chinese Medical Journal, 2022
Gui Luo, Jian Zhu, Lishao Guo
doaj   +3 more sources

Axial spondyloarthritis

Medicine, 2022
Ankylosing spondylitis (AS) is an inflammatory condition that can result in avoidable pain and debilitation, if impactful treatment is not started early. Although it can be challenging to diagnose, once the diagnosis is made, it is imperative to promptly start on treatment.
Galloway, M, Machado, PM
  +5 more sources

Axial spondyloarthritis [PDF]

Nature Reviews Disease Primers, 2015
The term axial spondyloarthritis covers both non-radiographic disease and radiographic disease (also known as ankylosing spondylitis). Some studies have been performed to investigate the prevalence of axial spondyloarthritis, although most are limited to patients with radiographic disease.
Joachim, Sieper, Jürgen, Braun, Maxime, Dougados, Dominique, Baeten   +3 more
openaire   +4 more sources

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set : translation and cross-cultural adaptation into 15 languages [PDF]

, 2016
Introduction: The Assessments of SpondyloArthritis international society Health Index (ASAS HI) measures functioning and health in patients with spondyloarthritis (SpA) across 17 aspects of health and 9 environmental factors (EF).
Bautista-Molano, W, Boonen, A, Braun, J, Burgos-Vargas, R, Chiowchanwisawakit, P, Duruoz, T, El-Zorkany, B, Essers, I, Gaydukova, I, Gossec, L, Grazio, S, Gu, J, Géher, P, Khan, MA, Kiltz, U, Kim, TJ, Maksymowych, WP, Marzo-Ortega, H, Navarro-Compán, V, Olivieri, I, Patrikos, D, Pimentel-Santos, FM, Schirmer, M, Van den Bosch, Filip, van der Heijde, D, Weber, U, Zochling, J   +26 more
core   +18 more sources

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review

BMC Musculoskeletal Disorders, 2022
Background Optimal treatment of nonradiographic axial spondyloarthritis depends on accurate and timely diagnosis of the underlying disease; however, patients present with common symptoms that, in the absence of radiographic changes, may confound ...
Philip Mease, Atul Deodhar
doaj   +1 more source

MRI Workshop for Axial Spondyloarthritis 2023 Interpretation of MRI SI Joint

Journal of Clinical Rheumatology and Immunology, 2023
MRI sacroiliac joint is a sensitive imaging modality for evaluation of inflammation and the accompanying structural changes. Assessment of SpondyloArthritis international Society (ASAS) classification criteria incorporates active inflammation of the ...
Victor LEE
doaj   +1 more source

Axial spondyloarthritis [PDF]

Vnitřní lékařství, 2018
Axial spondyloarthritis (axSpA) is a common name for the non-radiographic form of the disease and radiographic axial spondyloarthritis, known as ankylosing spondylitis (AS). The disease is typically manifested at a young age, characterized by affection of axial skeleton, and in the most severe form can lead to complete ankylosis of the spine.
Leona, Procházková, Vladimír, Červeňák, Miroslav, Souček   +2 more
openaire   +2 more sources

Ankylosing spondylitis-axial spondyloarthritis

Indian Journal of Rheumatology, 2017
Aanand Narayan Malaviya
doaj   +2 more sources

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources